PTPRC and acute myeloid leukemia: Though leukemia cells express multiple surface antigens that could be targeted, clinical RIT trials to treat AML have primarily used anti-CD33, anti-CD66 and anti-CD45 Ab as vehicles to deliver radiotherapy.